Default Lay summary
Hier wird in Kürze eine laienverständliche Zusammenfassung der Studienresultate veröffentlicht.
Original-Studienbeschreibung
blabla
PI
Prof. Reinhard Dummer
Abgeschlossene Studie
Melanom: A Phase 3, Randomized, Open-label Study of Bempegaldesleukin (a modified Interleukin-2) combined with Nivolumab (anti-PD-1 Monoclonal Antibody) versus Nivolumab in Participants with previously Untreated Unresectable or Metastatic Melanoma
Stadium/Indikation inkl. Kurzinfo
Melanom – 1st line
Stadium III oder IV
Anti-PD1 + modified IL12 vs Anti-PD1
Kurztitel
BMS CA045-001
NCT03635983
Offizieller Titel
A Phase 3, Randomized, Open-label Study of Bempegaldesleukin (a modified Interleukin-2) combined with Nivolumab (anti-PD-1 Monoclonal Antibody) versus Nivolumab in Participants with previously Untreated Unresectable or Metastatic Melanoma